The effective treatments for central nervous system (CNS) diseases are impeded mostly by the existence of the blood-brain barrier (BBB). The accumulation of therapeutic drugs inside the brain is far from the therapy threshold, which is closely related to the transient circulation time of drugs and their carriers. Herein, a core-shell protein-based long-circulation delivery platform was constructed. Through in situ free radical polymerization, a zwitterionic polymer poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) was modified on the surface to prolong the circulation lifetime with a biomimetic structure induced by a phosphorylcholine (PC) head-group similar to the lipids in the outer membrane of living cells. A cellpenetrating peptide, HIV-1 trans-activating transcriptor (TAT) was conjugated on the surface of the protein-based nanoparticles, endowing the delivery platform with BBB-crossing ability. The BBBpermeability of the nanoparticles was investigated both in vitro and in vivo. Encapsulated with zwitterionic polymer PMPC, the nanoparticles showed a long circulation lifetime due to strong resistance to nonspecific adsorption and provided a better chance for BBB penetration. The delivery platform had enhanced permeability for BBB and a longer retention time inside the brain in a healthy mouse model. Overall, the surface modification with zwitterionic polymer PMPC and cell-penetrating peptide TAT changes the circulation modality of the nanoparticles in vivo, and provides a promising pathway for BBB crossing as a potential drug delivery platform for CNS related disease therapy.
Introduction
Central nervous system (CNS) related diseases have an increasing occurrence now due to the aging of the population. However, effective therapies are greatly impeded by the strictly selective permeability of the blood-brain barrier (BBB). [1] [2] [3] This high selectivity of the BBB results from the tight junctions (TJs) between endothelial cells in CNS capillaries, 4 and the existence of P-glycoprotein (P-gp) on the cell membrane of brain capillaries which can rapidly pump the intrusive therapeutic agents out of the brain and back to the blood circulation. 5 These specic features make it rather difficult for CNS therapeutic agents to reach the diseased brain sections or remain there for sufficient time. In recent years, various therapeutic BBB carriers have been developed for CNS diseases, 6 such as chemical delivery systems, 7, 8 carrier-mediated transports, 9-11 molecular Trojan horses, [12] [13] [14] [15] and colloidal carriers. 16, 17 However, the therapeutic efficacy of these delivery systems is barely satisfactory from expectation, resulting from their limited penetration and retention ability. Therefore, the drug concentration in the diseased sections is much lower than the threshold for therapy. To address these problems, receptormediated BBB delivery systems have been considered as a powerful strategy to promote BBB penetration efficacy. Many researchers have focused on searching for specic receptors which are over-expressed on the BBB cell membrane to gain access to the brain with the required concentration for therapy. Various systems have been developed based on this assumption, including receptors for transferrin, 18 insulin, 19 diphtheria toxin, 20, 21 and nicotinic acetylcholine. [22] [23] [24] However, the BBB penetration efficiency is still not satisfactory due to factors such as the usually saturated binding sites under normal conditions in vivo. 4 Learning from successful strategies for the treatment of tumors in other parts of the body, 25, 26 a prolonged circulation time of the delivery system is always able to enhance tumor targeting and accumulation. This seems to indicate that the circulation time of the delivery system may play a key role in BBB penetration. [27] [28] [29] To one's surprise, the importance of the in vivo circulation ability of the BBB carriers has long been ignored in the treatment of CNS diseases. It is well known that PEGylation is the most widely used strategy to prolong the circulation lifetime of various delivery systems. Nevertheless, due to the progression of the immune response to the polyethylene glycol (PEG) shell and the signicantly accelerated blood clearance, the therapeutic efficacy of PEGylated nanocarriers for CNS diseases is greatly restricted. [30] [31] [32] [33] [34] [35] In this respect, a novel delivery system with lower immune response and longer circulation time is urgently needed. Inspired by the excellent stability and long circulation ability of cells under blood circulation and normal physiological conditions, the composition of the outer bilayer membrane of living cells arouses the interest of many scientists. The biomembrane of cells is mainly constructed of natural phospholipid molecules. Therefore, it is reasonable to deduce that a material which can mimic this special structure will meet the requirements mentioned above to the greatest extent. Owing to its similar structure to the headgroup of phosphorylcholine (PC) lipids in the outer surface of living cells, the zwitterionic polymer poly(2-methacryloyloxyethyl phosphorylcholine) (PMPC) shows excellent hydrophilicity, biocompatibility, stability and bioavailability, which have even been conrmed clinically. [36] [37] [38] [39] PMPC encapsulation empowers the nanocarriers with a biomembrane-like structure, providing a biocompatible chemical structure which is the basis for an ability to circulate for a long time in the blood. [40] [41] [42] Jiang and co-workers have demonstrated that PMPC shows a high non-fouling property of excellent resistance to nonspecic protein adsorption, which can reduce its quick recognition by the immune system and delay blood clearance. [42] [43] [44] [45] [46] Consequently, coating with PMPC will endow the BBB delivery shuttles with a stealth property and therefore much longer circulation-lifetime in vivo with a better chance to contact with and penetrate through the BBB cell membrane.
As a proof of the concept whether circulation time is a key factor in BBB penetration, we report here for the rst time a facile approach of constructing a protein-based biomimetic nanoplatform encapsulated with zwitterionic polymer PMPC and conjugated with HIV-1 trans-activating transcriptor (TAT) peptides to penetrate the BBB. The advantages of this delivery platform can be listed as follows: (1) encapsulation with PMPC endows the delivery shuttle with a stealth property and therefore much longer circulation-lifetime in vivo with little or even no immune response; [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] (2) as the mechanism of TAT entering the CNS is the temporary disruption of the BBB mainly by decreasing the expression of and altering the distribution of TJs proteins, 57-67 the delivery system conjugated with TAT can remain inside the brain parenchyma with reduced pumping back to blood circulation; (3) the model protein core can be replaced by any type of active protein, empowering the delivery system with additional therapeutic effects for different CNS diseases.
Experimental

Materials
Bovine serum albumin (BSA), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), dimethyl sulfoxide (DMSO), CHCl 3 , HCl, trimethylamine and NaHCO 3 were purchased from Aladdin Reagent Database Inc. (Shanghai, China). N-Hydroxy-succinimide ester (NAS), N,N Preparation of zwitterionic polymer capsuled protein-based nanogel (nBSA)
The typical procedure for the preparation of zwitterionic polymer capsuled protein-based nanogel via in situ free radical polymerization directly on the surface of aBSA is described below: an aqueous solution of 118.1 mg of MPC, 15.0 mg of BIS, 29.4 mL of TEMED and 5.0 mL of the above 0.5 mg mL À1 aBSA solution was added to a ask. The mixture was bubbled through nitrogen for 0.5 h to remove residual oxygen at room temperature. Then 11.0 mg of APS was rapidly added and the polymerization was allowed to proceed for an additional 3 h in a nitrogen atmosphere at room temperature. Finally, dialysis (MWCO: 100 kDa) was used to remove monomers and initiators in 20 mM PB solution (pH 7.4) for 48 h (fresh PB solution was replaced every 6 h) to give an nBSA solution.
Bioconjugation of TAT with zwitterionic nanogel (TAT-nBSA)
The bioconjugation of cell penetrating peptide TAT with zwitterionic and protein-based nanogel was similar to that of BSA nanogel by modifying the protein-based nanogel using a conjugating technique. An aqueous solution of 118.1 mg of MPC, 1.4 mL of AA, 15.0 mg of BIS, 29.4 mL of TEMED and 5.0 mL of the above 0.5 mg mL À1 aBSA solution was added to a ask.
The mixture was bubbled through nitrogen for 0.5 h to remove residual oxygen at room temperature. Then 11.0 mg of APS was rapidly added and the polymerization was allowed to proceed for an additional 3 h in a nitrogen atmosphere at room temperature. Finally, dialysis (MWCO: 100 kDa) was used to remove monomers and initiators in 20 mM PB solution (pH 7. Preparation of Cy5.5 labeled protein-based nanogel 0.4 mg of Cy5.5 was dissolved in 0.5 mL of DMSO. Then the solution was added dropwise to 5.0 mL of BSA solution (concentration of BSA was 0.5 mg mL À1 ) and stirred for 1 h at room temperature in a dark place. Subsequently the solution was dialyzed against 20 mM PB solution (pH 7.4) for 12 h (MWCO: 1000 Da) and fresh PB solution was exchanged every 4 h. To determine the content of Cy5.5 in the BSA solution, the solution was lyophilized and then redissolved in DMSO. The amount of Cy5.5 in the nanogel was determined by measuring the absorbance at 680 nm with a UV-Vis spectrophotometer. All the Cy5.5 labelled BSA-based nanogels were obtained from modications based on this Cy5.5-labeled BSA to ensure the same amount of Cy5.5 in each sample.
Characterizations
Dynamic light scattering (DLS). Dynamic light scattering (DLS) was used to measure the size, size distribution and zeta potential of particles in aqueous solution and was carried out with a Malvern Zetasizer Nano S instrument (Malvern Instruments Ltd) equipped with a 4.0 mW He-Ne laser operating at l ¼ 633 nm. All samples (0.5 mg mL À1 of BSA) were measured at a scattering angle of 90 in 20 mM phosphate buffer (PB) at room temperature (25 C).
Transmission electron microscopy (TEM). Transmission electron microscopy (TEM) studies were performed with a Tecnai G2spirit Biotwin instrument at a voltage of 120 kV (FEI, USA). Samples were prepared by drop-casting solutions onto carbon-coated copper grids, and then air-drying at room temperature. Then the samples were negatively stained by 1% phosphotungstic acid (pH ¼ 7.0) before measurement.
31 P nuclear magnetic resonance spectroscopy (NMR).
31
P nuclear magnetic resonance spectroscopy (NMR) spectra were recorded using a Varian Mercury Plus 400 MHz spectrometer to conrm the attachment of PMPC onto the nanoparticles. Samples were prepared by dissolving in 50% H 2 O/50% D 2 O at 0.25 mg mL À1 and the pH was adjusted to 7.4.
Flow cytometry (FCM).
Flow cytometry (FCM) was assessed using a ow cytometer (Accuri C6, Becton, Dickinson and Company, Shanghai, China). TAT was labeled with FITC in pH ¼ 8.5, 20 mM PB. Non-TAT modied (used as control to draw the gate) and FITC-labeled TAT-modied nanoparticles were recorded in a ow cytometer (100 000 nanoparticles studied) to conrm the attachment of TAT onto the system. SDS-PAGE. SDS-PAGE gel electrophoresis was carried out to determine the molecular weight of the nanoparticles. Native BSA, nBSA, and three TAT-modied systems were used as samples and Protein Ladder (purchased from Beyotime, Shanghai, China) was used as the maker. Precast gel was purchased from Willget Biotech Co., Ltd, Shanghai, China. Aer staining and decolourization for three days, the results were shown in BIO-RAD Gel Doc XR+ (BIO-RAD, USA).
Cell culture and animals
L929 (mouse broblast cells), C6 (mouse glioma cells) were purchased from the Shanghai Institute for Biological Sciences, Chinese Academy of Sciences Institute of Cell Resource Center (Shanghai, China). L929 cells were cultured using a medium of DMEM-high glucose with 10% FBS and 1% penicillinstreptomycin. C6 cells were cultured in a medium of DMEM/ F12k (1 : 1) with 10% FBS and 1% penicillin-streptomycin. Rat brain-derived microvascular endothelial cells (RBMEC), astrocytes (RBAC) and pericytes (RBPC) and corresponding complete medium were all purchased from CHI Scientic, Inc., Jiangyin, China. Cells were cultured at 37 C with 5% CO 2 .
KM mice and BalB/C nude mice were purchased from Shanghai SLAC Laboratory Animal CO. LTD. (Shanghai, China). Animals were placed in a particular pathogen-free animal house with free access to food and water. 
In vitro cytotoxicity assay
The cytotoxicity of the delivery system was assessed using MTT assay. L929 cells were plated in a 96-well plate at a cell density of 1.0 Â 10 4 cells per well and incubated for 24 h at 37 C and 5% CO 2 before they were treated with different concentrations of TBSA, nBSA and TAT-nBSA, respectively. All samples were incubated with the cells for 24 h. Before the MTT assay, each well was relled with fresh medium. For the MTT assay, 20.0 mL of 5.0 mg mL À1 MTT (Beyotime Institute of Biotechnology, Shanghai, China) solution was added to each well and incubated for 4 h at 37 C. Aer dissolving the formed fomazan with 150.0 mL of DMSO in each well, the plates were shaken for 5 min with a shaker. The absorbance (OD value) was measured at 490 nm with a microplate reader. The cytotoxicity was measured by comparing it with the absorbance at each concentration and the control group.
Cell internalization of delivery system
The cell internalization assay was assessed using a ow cytometer (Accuri C6, Becton, Dickinson and Company, Shanghai, China). L929 and C6 cells were plated in 6-well plates at a cell density of 2 Â 10 5 cells per well and incubated for 24 h at 37 C and 5% CO 2 before they were treated with 62.5 mg mL
À1
FITC-labeled TBAS, nBSA and TAT-nBSA, respectively. Aer treatment for 0.25, 0.5, 1, 2 and 3 h, respectively, the cells were washed with PBS three times and digested with 0.05% trypsin EDTA (Gibco, Life Technologies, Shanghai, China). Aer conguration at 10 4 rpm for 5 min, the cells were resuspended with 500.0 mL of fresh medium (without FBS). The control group was analyzed rst by ow cytometer to draw the gate and all the other tested groups were collected and recorded with a limit of P 1 ¼ 10 K in the gate. The uorescence signal of the labeled FITC was collected in the rst channel named FL1. All other groups were collected in the same way as the control group. For in vitro imaging, C6 cells were seeded on 6-well plates at a density of 1 Â 10 5 cells per well with a cover glass on the bottom. Aer 24 h, 62.5 mg mL À1 FITC-labeled TBAS, nBSA and TAT-nBSA were incubated with cells for 0.25, 0.5, 1, 1.5, 2 and 3 h, respectively, at 37 C. To remove the free conjugates, the cells were washed three times for 5 min with PBS and xed in 3.7% formaldehyde solution (1.0 mL per well) for 30 min. The nuclear dye DAPI was used to stain the nuclei in the experiment. Images of cells were acquired using a Zeiss LSM 5 Pascal Confocal laser scanning microscope (Carl Zeiss AG, Oberkochen, Germany) imaging system.
In vitro BBB model-based assay
The in vitro BBB model was established using a primary coculture with RBMEC, RBAC and RBPC, as described by Deli et al. A collagen-coated 0.4 mm PTFE membrane of the transwell inserts (12 well, Corning Life Sciences, MA, USA) was used. RBPC were seeded on the bottom side of the inserts at a density of 1.5 Â 10 4 cells cm À2 and RBAC were seeded on the bottom of the plate at the same density on day 1. The cells were allowed to undergo strong adhesion overnight. Then RBMEC were seeded on the upper side of the insert-chamber of the 12-well culture plates, and RBAC were seeded on the bottom of this culture plate, with a density of 1.5 Â 10 5 cells cm À2 on day 0. From day 1, the BBB models were maintained in RBMEC medium, supplemented with 500.0 nM hydrocortisone. The media was changed every other day and the in vitro BBB models were put into use from day 4. When trans-epithelial electric resistance (TEER) reached 250.0 U cm 2 by subtraction of the resistance of an insert without cells, this showed that the in vitro BBB model was ready for the permeability assay. TEER was recorded using an Autolab PGSTAT302N (Metrohm, Switzerland) electrochemical test system and calculated using equation (eqn (1)):
where A is the area of the lter in cm 2 . The model was characterized by immunochemistry analysis and electron microscopy. Aer washing and xation, RBMEC were incubated with antivon Willebrand factor rabbit polyclonal antibody, RBAC with anti-GFAP mouse monoclonal antibody, and RBPC with antialpha smooth muscle actin antibody (Abcam, Shanghai, China). All primary antibodies were used in 1 : 100 dilution. As secondary antibodies FITC conjugated goat anti-rabbit IgG (from CHI Scientic, Inc., Jiangyin, China) were used in a dilution 1 : 1000. A Zeiss LSM 5 Pascal confocal microscope (Carl Zeiss AG, Oberkochen, Germany) was used to examine the staining. Cells grown on the membrane were xed with 2.5% glutaraldehyde for 30 min at 4 C. Aer washing with 0.1 M PBS three times, the membranes of the culture inserts with the cells on the two sides were removed from their support and placed into a 24-well chamber slide and were postxed in 1% OsO 4 for 1 h. Following washing with 0.1 M PBS, the cells on the membrane were gradient dehydrated using ethanol, block-stained with resin in 99% acetone (1 : 1) for 1 h and embedded in 100% resin. A Leica UC6 ultramicrotome (Leica Microsystems, Milton Keynes, UK) was used to give ultrathin sections cut perpendicularly and a 120 kV biology transmission electron microscope (Tecnai G2 spirit Biotwin, FEI, USA) was used to examine the ultrathin membranes. For the permeability assay, 0.5 mg mL À1 FITC labeled TBSA, nBSA and TAT-nBSA were added to the upper chamber of the transwells to yield a nal concentration of 62.5 mg mL À1 . At 20, 40 and 60 min post-treatment, inserts were moved to new well where fresh PBS was contained. The concentrations of transported nanoparticles were measured by ow cytometry and analyzed using the standard curve method. Transport was expressed as microliters of donor (luminal) compartment volume from which the tracer was completely cleared. The permeability coefficients (P e , cm s À1 ) for the nanoparticles were calculated as previously described. 4, 70 Cleared volume was calculated from the concentration (C) of the nanoparticles in the basolateral side (BL) and apical side (AP) compartments and the volume (V) of the BL compartment by the following equation (eqn (2)):
The average cleared volume was plotted versus time, and the permeability multiplied by the surface area product value for the endothelial monolayer (PS e ) was calculated by the following formula (eqn (3)):
PS e divided by the surface area generated the endothelial permeability coefficient (P e , in 10 À6 cm s À1 ).
In vivo imaging studies
Whole-body in vivo biodistribution and brain accumulation in healthy Balb/C nude mice was examined using an eXplore Optix MX animal optical molecular imaging system (General Electric Company, USA) at 580 nm excitation and 692 nm emission wavelengths. Each mouse was injected in the tail vein with 200.0 mL per mouse of Cy5.5 labeled 0.5 mg mL À1 TBSA, nBSA and TAT-nBSA, respectively. Then the mice were given general anesthesia with glutaraldehyde (2%). At time points aer injection of 0.5, 1, 2, 3, 4, 5, 6, 24, 48 and 72 h, the mice were xed with tapes and pictures taken from the back.
In vivo circulation time study
The in vivo circulation times of TBSA, nBSA and TAT-nBSA nanoparticles were investigated in healthy KM mice ($40 g). The FITC-labeled TBSA, nBSA and TAT-nBSA nanoparticles were injected into the tail vein intravenously at a dose of 3.0 mg kg À1 (concentration of BSA) with three mice in each group. Time points selected for the nanoparticles were 0, 2, 6, 10, 24, 48, and 72 h post-injection. At each time point, mice were sacriced and blood samples were collected in coagulating tubes to give serum. The samples were stored at 4 C until analysis. The serum of each sample was analyzed using UV-Vis. The absorbance of each sample at 388 nm was recorded. The residual content in plasma at each time point was calculated as follows:
Residual content (%) ¼ Abs time point /Abs 0 h Â 100
Biodistribution in tissues
Healthy 5-6 week male BalB/C mice, ve mice for each group, were injected in the tail vein with 200.0 mL per mouse of FITC labeled 0.5 mg mL À1 TBSA, nBSA and TAT-nBSA. Mice treated with the same amount of saline were used as a blank control. The mice for the biodistribution test were sacriced by cervical dislocation aer bloodletting from the retinal vein plexus 2 h and 24 h post-injection. The blood was collected in procoagulation tubes to get the serum. The brain tissues, hearts, livers, spleens, lungs and kidneys of each mouse were separated, weighed and washed three times with ice-cold PBS. The tissues were ultrasonically decomposed by an Ultrasonic Processor (Scientz-IID, Ningbo Scientz Biotechnology CO., LTD, Ningbo, China) at a concentration of 100.0 mg weight tissue per milliliter of PBS. Aer centrifugation, the supernatant was collected and the uorescence intensity (FI) of each sample was tested by a uorescence spectrophotometer. The uorescence intensity of each experimental sample was corrected by subtracting the uorescence intensity value of the blank control.
The nal results were expressed as the percentage of FI of each tissue to the summary of all the organs of each mouse.
Fluorescence microscopic examination of traversing the BBB 5-6 week healthy male BalB/C mice, ve mice for each group, were injected in the tail vein with 200.0 mL per mouse of FITC labeled 0.5 mg mL À1 TBSA, nBSA and TAT-nBSA. The mice for the uorescence intensity test were sacriced by cervical dislocation at 1, 3, 9, 24, 48 and 72 h aer i.p. injection, respectively. Brain tissues of each mouse were separated, weighed and washed once with PBS. The brains were ultrasonically decomposed at a concentration of 100.0 mg weight tissue per milliliter of PBS. Aer centrifugation, the uorescence intensity of each collected supernatant was tested by a uorescence spectrophotometer.
To investigate nanoparticle accumulation inside the brain tissues, FITC-labeled nanoparticles (200.0 mL injection volume; 0.5 mg mL À1 nanoparticles in solution) were injected into the tail veins of 5-6 week healthy male BalB/C mice. 1, 2 and 24 h post treatment, the mice were sacriced by cervical dislocation and their brains were separated and collected. The brain slices were taken by a freezing microtome section, 10 mm in thickness, and every 20th slice was kept (Cryotome E, Thermo Fisher Scientic, USA). The air-dried samples were imaged using a Zeiss LSM 5 Pascal Confocal laser scanning microscope (Carl Zeiss AG, Oberkochen, Germany). Pictures were taken from the lower le part of each slice (Ex./Em. ¼ 488/518 nm).
To further conrm the intracerebral location of the nanoparticles and the relationship with the blood vessels, FITClabeled nanoparticles (200.0 mL injection volume; 0.5 mg mL À1 nanoparticles in solution) were injected into the tail vein of 5-6 week healthy male BalB/C mice, 2 in each group. 2 h post treatment, the mice were sacriced by cervical dislocation and their brains were separated and immersed in 4% paraformaldehyde overnight. The brain tissues were washed with PBS 3 times, each for 30 min, and immersed in 20% sucrose solution overnight and kept at 4 C. The brain slices were taken by a freezing microtome section, 10.0 mm in thickness, and every 20th slice was kept (Cryotome E, Thermo Fisher Scientic, USA). The air-dried slices were xed with cold acetone for 10 min and washed with PBS 3 times, 5 min each time. EDTA antigen repair buffer (pH ¼ 8.0) was used to repair the slices within a microwave for 10 min. Aer air-drying, the slices were washed with PBS 3 times, 5 min each time. Aer blocking with 3% BSA in PBS for 30 min at room temperature, the slices were incubated with an antibody against PECAM-1 (CD31) (BD Biosciences) overnight at 4 C. Cy-3 conjugated secondary antibody (Invitrogen Carlsbad, CA) was applied for 1 h at room temperature, together with DAPI. Samples were analyzed with a uorescence microscope (Nikon Eclipse TI-SR, Japan).
Statistical analysis
The results were analyzed using Tukey's honest signicant difference test for multiple comparisons followed by John Wilder Tukey's test to identify signicant differences between groups. The family-wise signicance and condence level was p < 0.05. All results were expressed as means AE standard error of mean (SEM).
Results and discussion
In this study, core-shell protein-based nanocarriers with long circulation ability (Fig. 1) have been developed via three typical steps according to our previous procedures. 68, 69 Bovine serum albumin (BSA) was chosen as the single-sized model protein core to guarantee an ultra-small size and a uniform size distribution of the nanoparticles. Then the PMPC shell could ensure a long delivery system lifetime in vivo and a biomembrane-like structure. The existence of a PMPC outer layer on the surface of MPC-modied BSA (nBSA) was conrmed by 31 P nuclear magnetic resonance spectroscopy ( 31 P NMR). As shown in Fig. 2a , the clean peak of MPC is at 0.57 ppm and native BSA shows no signal. The spectrum of nBSA shows peaks at 0.40 ppm, which represent the successful attachment of MPC onto the BSA surface. Meanwhile, to provide carboxyl groups for the conjugation of TAT, acrylic acid (AA) was introduced. As shown in Fig. 2f , the zeta potential of nBSA is À4.49 mV. Aer the introduction of AA, this decreases to À9.55 mV in acrylic nBSA. With the conjugation of TAT peptide onto the surface, the transport ability as well as the concentration and retention time of the nanoparticles inside brain will be extremely improved. To conrm the attachment of TAT peptides on the surface of the delivery platform (TAT-nBSA), TAT was labeled with FITC and the uorescence signal of the nanoparticles was collected and analyzed. Compared with non-TAT-modied nBSA (Fig. 2b) , TAT-modied TAT-nBSA nanoparticles show an extra FITC uorescence signal (Fig. 2c) , from which the attachment of TAT peptides on the surface of the delivery system can be conrmed. With different amounts of TAT conjugated on the surface, a series of nanoparticles were obtained (TAT-1-nBSA, TAT-5-nBSA and TAT-10-nBSA, where the number stands for the molar ratio of TAT to BSA). The molecular weight (MW) of the resulting delivery platforms was characterized by SDS-PAGE (Fig. 2d) . Native BSA shows an MW around 65 kD. Aer surface modication, the MW of nBSA and TAT-nBSA increases to around 120 kD. With several modication steps, the particle size and surface property were also changed. With the help of dynamic light scattering (DLS) and a transmission electron microscope (TEM), the size and morphology parameters of the BSA-based nanoparticles were recorded (Fig. S1 †) . As shown in Fig. 2e and f, TBSA, nBSA, acrylic nBSA and TAT-nBSA show differences in size but are similar in zeta potential, close to electrical neutrality. The sizes of the nanoparticles increase from 5.24 nm to around 22.00 nm aer modication, and the zeta potentials of TAT-nBSA are around À7 mV ( Table 1 ). The TEM images in Fig. 2g-i show that TBSA, nBSA and TAT-1-nBSA exhibit uniform spherical nanoparticles and well-dened size distributions, which correspond to the results of DLS observation very well. No signicant morphological changes can be observed aer the surface modications, as evidenced by TEM imaging.
The biocompatibility of the materials is important for the delivery system. Here we used MTT to examine the cytotoxicity of the nanoparticles. As shown in Fig. S2a , † aer the incubation of L929 cells with TBSA, nBSA, TAT-1-nBSA, TAT-5-nBSA and TAT-10-nBSA for 24 h, over 80% of the cells can survive even aer co-incubation with an extremely high concentration (125.0 mg mL À1 ). The MTT assays conrm the low in vitro cytotoxicity of these nanoparticles. The cell internalization ability of the delivery platform is the basis of in vivo BBB crossing efficacy. Herein we rst tested the cell internalization ability with monolayer cells. As observed by confocal microscopy (Fig. S2b †) , aer 3 h of incubation, a small amount of non-TAT-modied nanoparticles is observed in C6 cells and localized in the cytoplasm. In contrast, TAT-modied nanoparticles (TBS, TAT-1-nBSA, TAT-5-nBSA and TAT-10-nBSA) can largely enter C6 cells. Among these four TAT-modied groups, the TAT-10-nBSA group shows the greatest permeability. To further demonstrate the extra cell penetrating ability of TAT-modied nanoparticles, quantitative results of ow cytometric analysis were collected ( Fig. S2c and d †) . With the increase in incubation time, the amount of TAT-modied nanoparticles internalized increases in both L929 and C6 cell lines. During the observed 3 h, the total amount of nanoparticles that penetrate the cell membranes is much higher for the TAT-modied groups than for the non-modied group both in L929 cells and C6 cells. In particular, for the TAT-10-nBSA group, 28.2% of all the nanoparticles can go into the L929 cells and 65.2% into the C6 cells, while the numbers for the TBSA group are 10.3% and 24.3%, for TAT-1-nBSA group they are 2.7% and 13.8%, and for TAT-5-nBSA group they are 10.7% and 29.2%, respectively. In contrast, for non-modied group nBSA nanoparticles, there are only 0.7% and 0.6% nanoparticles internalized by the cells. In summary, the conjugation of TAT peptide on the surface of nanoparticles can signicantly improve cell internalization ability. The enhanced cell uptake of TAT-modied nanoparticles is benecial for improving the potential drug delivery efficiency. Besides, for broblast cells and glioma cells in our study, the delivery system shows a propensity for much more internalization by the glioma cells no matter in which TBSA, TAT-1-nBSA, TAT-5-nBSA or TAT-10-nBSA group, and this might be a hint for targeting delivery in vivo.
To further demonstrate the cell transport ability in a model much more similar to the real BBB in vivo than the monolayer cell lines, we constructed an in vitro BBB model to test the permeability efficacy of the delivery platforms. The set-up of the BBB model is shown in Fig. 3a , as previously described by Deli and co-workers.
70 Rat brain microvascular endothelial cells (RBMEC) grew into a non-overlapping continuous monolayer lm, showing close connections with each other, small size, and positive staining for von Willebrand factor (Fig. 3c) . Rat brain astrocyte cells (RBAC) give positive immunostaining for GFAP, resembling astrocytic endfeet with a distinct morphology (Fig. 3b) . Rat brain pericyte cells (RBPC) are different from RBMEC and RBAC both in morphology and size and have a large spread with irregular projections, and they are positive for alpha-smooth muscle actin immunostaining (Fig. 3d) . From the TEM images (Fig. 3e) it can be clearly observed that with the existence of both RBAC and RBPC, RBMEC grow on the membrane of the transwell with TJs and kissing points (white arrows in Fig. 3e) .
The integrity of the RBMEC monolayer in the in vitro BBB model was monitored by the trans epithelial electric resistance (TEER) value during the experiments, which was typically above 250.0 U cm 2 . The permeability coefficients P e of the different groups are collected in Table 2 . This reveals that TAT-5-nBSA possesses the most prominent transport capability with an endothelial permeability coefficient P e of 17.703 Â 10 À6 cm s À1 compared to other groups. 4.09% of initial TBSA, 3.93% of initial TAT-1-nBSA, 4.29% of initial TAT-5-nBSA and 2.43% of initial TAT-10-nBSA nanoparticles are found in BL aer 60 min of incubation, but only 0.75% of non-TAT-modied nBSA could be detected under the same conditions. In addition to the . 3b ), RBMEC was positive for factor VIII-related antigen/von Willebrand factor (Fig. 3c) , and RBPC gave a positive immunostaining for alpha smooth muscle actin (Fig. 3d) . Scale bar was 100 mm for in monolayer cell line conditions, because of the existence of BBB in the in vitro BBB model, TAT shows both the penetration ability and the recognition effects of P-glycoproteins. Then the nal permeation efficacy is the competition of these two opposite abilities. We suppose that excess TAT peptides (10 times BSA in molar ratio in our case) will give rise to more easy recognition of the delivery system by the BBB rather than better transport efficiency. Thus we could draw a conclusion that the BBB-crossing permeability is proportional to the amount of TAT peptides on the surface within a certain range. Beyond that, this efficacy would decline as the number of TAT increases. No big difference can be seen between the TBSA and TAT-5-nBSA groups. However, in this in vitro BBB model, the total amounts of nanoparticles in each group at the beginning and end of the whole test are equal to each other, and they will not be metabolized or cleared as happens in the real animal. Under such conditions, the non-fouling shell made no difference. In order to show the real BBB-transport ability of the delivery systems, healthy nude mice were used for animal imaging. Firstly, through pharmacokinetic study, we can evaluate the circulation behavior of each group in vivo. As revealed in Fig. 4b , aer encapsulation of zwitterionic polymer PMPC on the surface, the in vivo lifetime of nBSA and TAT-nBSA groups can be more than 72 h, and their half-lifetimes were prolonged to about 24 h. In contrast, due to the lack of this non-fouling shell, TBSA showed short circulation time and will be quickly cleared from the blood with a half-lifetime of around 10 h. Based on this situation and difference, their BBB-permeability will be quite different from the in vitro BBB model-based test which takes no metabolism into consideration. As shown in Fig. 4a, 1 h aer intravenous injection, a strong near-infrared (NIR) uorescence signal shows up in the cerebral area and heart for both non-TAT-modied-nBSA and TAT-modied-nBSA groups. In contrast, non-PMPC-modied nanoparticles mainly located in lungs and kidneys due to their ultra-small size. 3 h aer injection, the signal in the brain becomes much weaker in the nBSA group, while the signal remains strong in this area for TATnBSA nanoparticles. Even aer 24 and 48 h, the uorescence signals of these three TAT-modied-nBSA groups remain strong in the brain and heart. However, weak signals continue to be present in the cerebral area of the control group treated with nBSA during the same time window. Conversely, due to its relatively short in vivo lifetime, TBSA was quickly cleared from the kidney and hence did not have much chance to contact with and penetrate through the BBB. Compared to the results in cell line conditions and the in vitro BBB model case, we can clearly see the difference between the TBSA and TAT-5-nBSA groups in BBB permeability. We propose that this difference mainly comes from their in vivo circulation time, which can be obviously changed by the modication of the zwitterionic polymer shell on the surface. These in vivo results strongly demonstrate the critical role of long circulation in crossing the BBB of the delivery platform.
In addition, to better understand the biodistribution and accumulation of the nanoparticles, major organs including brain, heart, liver, spleen, lung, kidney and serum were collected and analyzed 2 h and 24 h aer injection. As shown in Fig. 4d and S3, † for TBSA nanoparticle treated mice, 2 h postinjection, the uorescence signals are distributed extensively in serum (53.32%) lung (15.35%) and heart (14.79%), and less in the liver (1.09%). And a similar biodistribution can be observed for the TBAS group 24 h post-injection. And it was mainly cleared through the kidney. In the case of nBSA nanoparticle treated mice, 2 h post-injection, the uorescence signals were distributed extensively in serum (53.56%) and brain (21.72%), and less in the liver (3.65%). Nevertheless, aer 24 h, the nanoparticles nearly completely disappear from the brain (3.43%). In contrast, for TAT-modied-nBSA nanoparticles, there are still 25.94%, 28.58% and 27.75%, Fig. 5 Immunofluorescence image of mouse brain sections (10 mm) from animals injected with FITC-labeled TBSA, nBSA, TAT-nBSA 2 h postinjection of the mice, respectively. Blue is the nucleus, red is the blood vessels and green is the nanoparticles. The last row is the magnified version of the white box in merge. Scale bar ¼ 50 mm.
respectively, in the brain even 24 h aer treatment. The ability of these three groups of nanoparticles to go into the brain is much stronger than for the non-TAT-modied nBSA and nonzwitterionic polymer-modied TBAS. nBSA nanoparticles could go across the BBB in the rst 2 h aer injection maybe because of the existence of gaps in the BBB and their similar structure to the head-group of PC lipids in the outer membrane of living cells. Though the nBSA nanocarriers have a biomembrane-like structure, they would soon be expelled from the brain section due to the P-glycoproteins efflux pump on the BBB.
To make a further precise quantitative examination of the BBB-crossing ability of the nanoparticles, we used uorescence examination by uorescence spectrophotometer and imaging. As shown in Fig. 4b , the intracerebral retention time of the TATnBSA delivery systems is as long as 72 h according to the time window of the investigation period aer single intravenous injection. In contrast, though conjugated with TAT, the TBSA group cannot effectively penetrate through the BBB due to its short lifetime in vivo. The results (Fig. S5 †) show that TATmodication gives extra permeability of the BBB to the nanoparticles when compared with the non-TAT-labeled nBSA group. No matter whether 1 h, 2 h or 24 h post-injection, those nanoparticles could continue being seen inside the brain. In contrast, although nBSA nanoparticles could accumulate in the brain 1 and 2 h aer injection, they could not remain there later and could barely be seen 24 h post-injection. Moreover, the TAT-5-nBSA group shows a stronger ability to light the brain section than TBAS, TAT-1-nBSA and TAT-10-nBSA. As shown in Fig. 5 , 2 h aer tail vein injection, TAT-nBSA nanoparticles locate not only in the brain vascular endothelial cells but also in the brain parenchyma. However, for TBSA nanoparticles, though they can be largely internalized by brain vascular endothelial cells, due to their relatively short circulation time, hardly any can be observed in brain parenchyma. Comparing the results in Fig. 4c and S4, † the TBSA and nBSA groups show the worst ability to go across the BBB from the blood circulation.
Conclusions
In conclusion, the aim of this work is to verify if long circulation lifetime is a critical issue for nanocarriers to deliver biologically active substances through the BBB, which could develop new effective strategies for drug delivery into the brain. In this regard, we have successfully fabricated an albumin-based nanoparticle delivery platform TAT-nBSA with distinct sizes for BBB-crossing. TAT-nBSA could simultaneously serve as a long lifetime circulating vehicle and an effective BBB-crossing agent. The TAT-nBSA nanoparticles are not recognized by the multidrug efflux system and remain inside the brain even up to 72 h with a high ratio of nearly 30% to the initial dose. Thus, this delivery system would be a suitable candidate as a BBB nanocarrier in clinical practice, whether for chronic or acute treatment. Moreover, BSA used in this system is just a model protein, which could be replaced by any type of active protein such as catalase, transferrin or even antibiotics for various additional functions to assist different types of drugs to bind onto the proteins for various kinds of CNS-related diseases. We believe this potential BBB-crossing platform could act as a meaningful addition to satisfy the unmet clinical need for various types of CNS disorders.
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